Oxford, Oxfordshire, United Kingdom Oxford Technology Management appeared to be the VC, which was created in 1983. The main department of described VC is located in the Oxford. The venture was found in Europe in United Kingdom.
The real fund results show that this VC is 15 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2005. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. Opposing the other organizations, this Oxford Technology Management works on 17 percentage points less the average amount of lead investments. The usual things for fund are deals in the range of 1 - 5 millions dollars. The increased amount of exits for fund were in 2017.
The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the Oxford Technology Management, startups are often financed by Innovate UK, UK Innovation & Science Seed Fund, Simon Murdoch. The meaningful sponsors for the fund in investment in the same round are UK Innovation & Science Seed Fund, Oxford Capital Partners, IP Group Plc. In the next rounds fund is usually obtained by Oxford Capital Partners, Hygea VCT, UK Innovation & Science Seed Fund.
This organization was formed by Lucius Cary. We also calculated 3 valuable employees in our database.
For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. Among the most popular portfolio startups of the fund, we may highlight Gripable, Azellon Cell Therapeutics, Oxis Energy. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Information Technology, Electronics.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Applegreen Partners | - |
| British Airways | England, London, United Kingdom |
| Capitol Health Ltd | Australia, Docklands, Victoria |
| Consort Medical | Hemel Hempstead, Hertfordshire, United Kingdom |
| Fifth Province Ventures | County Dublin, Dublin, Ireland |
| Fireca | - |
| Ganexa Capital | Lisboa, Lisbon, Portugal |
| Great Stuff Ventures | - |
| Kunlun Capital | Central, Central Region, Singapore |
| Neglected Climate Opportunities | - |
| New England Partners | Massachusetts, Quincy, United States |
| Nurmiranta Holdings | - |
| Ping An Capital | China, Shanghai |
| PTT Public Company | Bangkok, Lat Yao Subdistrict, Thailand |
| PureTech Health | Boston, Massachusetts, United States |
| TNN Capital | Luxembourg, Luxembourg |
| Winton Labs | England, London, United Kingdom |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
CryoLogyx | $685K | 18 Mar 2024 | Coventry, Coventry, United Kingdom | ||
MitoRx Therapeutics | $5M | 13 Dec 2023 | Harwell, Oxfordshire, United Kingdom | ||
OxCan | $4M | 10 Jan 2023 | Oxford, Oxfordshire, United Kingdom | ||
Diffblue | $8M | 21 Nov 2022 | Oxford, England, United Kingdom | ||
MitoRx Therapeutics | 25 Apr 2022 | Harwell, Oxfordshire, United Kingdom | |||
OxCan | $1M | 06 Sep 2021 | Oxford, Oxfordshire, United Kingdom | ||
| 05 May 2021 | Oxford, England, United Kingdom | ||||
Lightpoint Medical | $7M | 25 Mar 2021 | United Kingdom, England, United Kingdom | ||
Gripable | $2M | 24 Mar 2021 | London, England, United Kingdom |
– Lightpoint Medical announced that it has completed an $8m financing round.
– The funding includes follow-on investment from private investors, Oxford Technology, Venture Founders, Coutts Bank, and new funding from the British Business Bank Future Fund.
– The new capital will be used to finance expanded clinical trials and early commercialization of Lightpoint’s robotic probe, SENSEI®, which has the potential to assist in over 2 million applicable surgical procedures every year in the EU, US, China and Japan.
– SENSEI® received CE Mark approval at the beginning of the year, has been registered successfully with the FDA, and has received approval for sale in Australia.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
CryoLogyx | $685K | 18 Mar 2024 | Coventry, Coventry, United Kingdom | ||
MitoRx Therapeutics | $5M | 13 Dec 2023 | Harwell, Oxfordshire, United Kingdom | ||
OxCan | $4M | 10 Jan 2023 | Oxford, Oxfordshire, United Kingdom | ||
Diffblue | $8M | 21 Nov 2022 | Oxford, England, United Kingdom | ||
MitoRx Therapeutics | 25 Apr 2022 | Harwell, Oxfordshire, United Kingdom | |||
OxCan | $1M | 06 Sep 2021 | Oxford, Oxfordshire, United Kingdom | ||
| 05 May 2021 | Oxford, England, United Kingdom | ||||
Lightpoint Medical | $7M | 25 Mar 2021 | United Kingdom, England, United Kingdom | ||
Gripable | $2M | 24 Mar 2021 | London, England, United Kingdom |
